Identification and Functional Mechanism Verification of Novel MicroRNAs Associated with the Fibrosis Progression in Chronic Kidney Disease

被引:3
作者
He, Kaiying [1 ,2 ,3 ]
Zhou, Xiaochun [2 ,3 ]
Zhao, Jing [1 ,2 ,3 ]
Du, Hongxuan [1 ,2 ,3 ]
Guo, Juan [4 ]
Deng, Rongrong [1 ,2 ,3 ]
Wang, Jianqin [2 ,3 ]
机构
[1] Lanzhou Univ, Lanzhou, Gansu, Peoples R China
[2] Lanzhou Univ, Hosp 2, Dept Nephrol, 82 Cuiyingmen, Lanzhou, Gansu, Peoples R China
[3] Lanzhou Univ, Clin Med Sch, 82 Cuiyingmen, Lanzhou, Gansu, Peoples R China
[4] Xian Huyi Dist Hosp Tradit Chinese Med, Xian, Shaanxi, Peoples R China
基金
中国国家自然科学基金;
关键词
Novel miRNAs; Chronic kidney disease; Renal fibrosis; DN; FSGS; PROMOTES RENAL FIBROSIS; PREVALENCE; MIR-21; TRENDS; EXPRESSION;
D O I
10.1007/s10528-024-10688-7
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Chronic kidney disease (CKD) is a serious threat to human health worldwide, and its incidence is increasing annually. A growing amount of information is emerging about the role of micoRNAs (miRNAs) in the regulation of renal fibrosis, which has aroused interest in the development of drugs that block pathogenic miRNAs or restore protective miRNAs levels. To clarify the role of miRNAs in CKD, we selected patients with significant renal fibrotic disease (diabetic nephropathy (DN) and focal segmental glomerulosclerosis (FSGS)) as the disease group, and patients with little or no renal fibrotic disease (minimal change disease (MCD) and renal carcinoma adjacent to normal kidney) as controls. Significantly differentially expressed miRNAs were obtained by human kidney tissue sequencing, subsequently verified in mice models of DN and FSGS, and subsequently inhibited or overexpressed in human renal tubular epithelial cells (HK-2) stimulated by high glucose (HG) and TGF-beta 1 in vitro. Therefore, the mechanism of its action in renal fibrosis was further elaborated. Finally, the downstream target genes of the corresponding miRNAs were verified by bioinformatics analysis, qRT-PCR, western blot and double luciferase report analysis. Two novel miRNAs, hsa-miR-1470-3p (miR-1470) and hsa-miR-4483-3p (miR-4483), were detected by renal tissue sequencing in the disease group with significant renal fibrosis (DN and FSGS) and the control group with little or no renal fibrosis (MCD and normal renal tissue adjacent to renal carcinoma). Subsequent human renal tissue qRT-PCR verified that the expression of miR-1470 was significantly increased, while the expression of miR-4483 was markedly decreased in the disease group (p < 0.05). Moreover, in vivo DN and FSGS mice models, the expression levels of miR-1470 and miR-4483 were consistent with the results of human kidney tissue. In vitro, miR-4483 was suppressed, whereas miR-1470 was induced by treatment with TGF-beta 1 or HG. Inhibition of miR-1470 or overexpression of miR-4483 promoted HG or TGF-beta 1-induced fibrosis in HK-2 cells. Further study revealed that MMP-13 and TIMP1 were the target genes ofmiR-1470 and miR-4483, respectively. Our study identifies newly dysregulated miRNA profiles related to fibrosis kidneys. miR-1470 and miR-4483 are demonstrated to participate in kidney fibrosis by regulation of MMP-13, TIMP1 respectively. Our results may represent a promising research direction for renal disorders and help identify new biomarkers and therapeutic targets for CKD.
引用
收藏
页码:4472 / 4493
页数:22
相关论文
共 50 条
[41]   Factors Associated with Chronic Kidney Disease Progression in Australian Nephrology Practices [J].
Boudville, Neil ;
Kemp, Anna ;
Moody, Henry ;
Fassett, Robert G. ;
Pedagogos, Eugenie ;
Nelson, Craig ;
Healy, Helen ;
Mangos, George ;
Kirkland, Geoff ;
Kay, Troy ;
de Crespigny, Paul Champion ;
Hoffman, David ;
Waugh, David .
NEPHRON CLINICAL PRACTICE, 2012, 121 (1-2) :C36-C41
[42]   Current and Novel Biomarkers of Progression Risk in Children with Chronic Kidney Disease [J].
Sandokji, Ibrahim ;
Xu, Yunwen ;
Denburg, Michelle ;
Furth, Susan ;
Abraham, Alison G. ;
Greenberg, Jason H. .
NEPHRON, 2023, :1-10
[43]   Identification of ferroptosis-associated genes in chronic kidney disease [J].
Shao, Lishi ;
Fang, Qixiang ;
Ba, Chaofei ;
Zhang, Yanqing ;
Shi, Chen ;
Zhang, Ya ;
Wang, Jiaping .
EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2023, 25 (01)
[44]   Epigenetics of Progression of Chronic Kidney Disease: Fact or Fantasy? [J].
Wing, Maria R. ;
Ramezani, Ali ;
Gill, Harindarpal S. ;
Devaney, Joseph M. ;
Raj, Dominic S. .
SEMINARS IN NEPHROLOGY, 2013, 33 (04) :363-374
[45]   Tubular toxicity of proteinuria and the progression of chronic kidney disease [J].
Makhammajanov, Zhalaliddin ;
Gaipov, Abduzhappar ;
Myngbay, Askhat ;
Bukasov, Rostislav ;
Aljofan, Mohamad ;
Kanbay, Mehmet .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 (04) :589-599
[46]   Progression of Tubulointerstitial Fibrosis and the Chronic Kidney Disease Phenotype - Role of Risk Factors and Epigenetics [J].
Hewitson, Timothy D. ;
Holt, Stephen G. ;
Smith, Edward R. .
FRONTIERS IN PHARMACOLOGY, 2017, 8
[47]   Retroperitoneal Fibrosis in Chronic Kidney Disease [J].
Yoshizaki, Yuki ;
Yui, Naofumi ;
Okado, Tomokazu ;
Ishigami, Junichi ;
Iimori, Soichiro ;
Oi, Katusyuki ;
Sohara, Eisei ;
Sasaki, Sei ;
Rai, Tatemitsu ;
Uchida, Shinichi .
JOURNAL OF GENERAL AND FAMILY MEDICINE, 2015, 16 (02) :103-106
[48]   Chemokine CCL9 Is Upregulated Early in Chronic Kidney Disease and Counteracts Kidney Inflammation and Fibrosis [J].
Hemmers, Christian ;
Schulte, Corinna ;
Wollenhaupt, Julia ;
Wong, Dickson W. L. ;
Harlacher, Eva ;
Orth-Alampour, Setareh ;
Klinkhammer, Barbara Mara ;
Schirmer, Stephan H. ;
Boehm, Michael ;
Marx, Nikolaus ;
Speer, Thimoteus ;
Boor, Peter ;
Jankowski, Joachim ;
Noels, Heidi .
BIOMEDICINES, 2022, 10 (02)
[49]   MicroRNAs and vascular damage in chronic kidney disease: advances and clinical implications [J].
da Cunha, Regiane Stafim ;
Azevedo, Carolina Amaral Bueno ;
Miniskiskosky, Guilherme ;
Gregorio, Paulo Cezar ;
Stinghen, Andrea Emilia Marques .
JORNAL BRASILEIRO DE NEFROLOGIA, 2025, 47 (03)
[50]   Acidosis and progression of chronic kidney disease [J].
Yaqoob, Muhammad M. .
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2010, 19 (05) :489-492